Tilray Q1 Loss Widens; Credit Facility Access Restricted by New Covenant Amendment
TLRY is trading near its 52-week low of $3.375 (7.1% above the low) on elevated volume (2.2× avg).
Summary
Tilray reported a $40.0M Q1 net loss and disclosed a new credit agreement amendment that limits borrowing availability until covenant tests resume.
Key Events · Earnings and Guidance · TLRY
-
Q1 Net Loss Widens to $40.0M
Net loss of $40.0M for Q1 FY2027 vs. a $1.5M profit a year ago. Operating expenses rose 83% to $101.6M, including $32.0M of incremental costs from the BrewDog and Lyphe acquisitions.
-
Credit Facility Access Restricted
Seventh Amendment dated October 7, 2026 suspends financial covenant testing for Q1 FY2027 and limits borrowing availability under the $15M revolving facility until covenant tests resume.
-
Debt-for-Equity Exchanges Continue
In September 2026, Tilray issued 2,841,650 shares to retire $12M of TLRY 27 Notes, reducing principal outstanding to $52M as of October 8, 2026.
-
Colcanna Divestiture Completed
Tilray sold its 90% ownership interest in Colcanna S.A.S. in September 2026 for nominal cash consideration, with the purchaser assuming all liabilities.
Analysis · TLRY · Life Sciences
Tilray's Q1 FY2027 net loss widened to $40.0M from a $1.5M profit a year ago, driven by a $46.2M jump in operating expenses tied to the BrewDog and Lyphe integrations. More importantly, the filing discloses a Seventh Amendment to its credit agreement that suspends covenant testing for the quarter and restricts access to the $15M revolving facility until compliance is re-established — a liquidity constraint that matters more than the headline earnings miss.
How filings like this one have moved
In the 30 days to Oct 8, 2026, 28.6% of the 1679 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TLRY was trading at $3.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $530.5M. The 52-week trading range was $3.38 to $23.20. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.